Attendee search 

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research.

Biotrak Capital is a healthcare-focused investment Fund with over 400M USD under management. In china but for global angle.

Jianmin Group is a integrated pharmaceutical company with a major focus on pediatric product development manufacturing, and marketing.

A Chengdu Based Chinese Pharmaceutical Company with focus on both Brand- Name/Generic Product Development, Manufacturing and Supply in Both Domestic and International Markets. Annual revenue is more than 175 million USD. We also have medical devices business unit starting from 2020.

Xi 'an Janssen Pharmaceutical Co., Ltd. is the largest pharmaceutical joint venture in China and the largest subsidiary of Johnson & Johnson in China. Founded in 1985, the company is headquartered in Beijing, with its production base located in Xi 'an and over 3,000 employees. The company's business includes the production and sale of high quality pharmaceuticals, mainly in the fields of gastroenterology, neuropsychiatry, allergy, pain management, anti-infection, biological agents and oncology.

Guangdong Fengle Group Co., Ltd. (hereinafter referred to as “Fengle Group”), established in 2004, is a diversified and comprehensive industrial group corporation integrated of industry, commerce and Finance.
Fengle Group focuses on energy, new energy, energy conservation and environmental protection, industrial investment and holding, and supply chain finance, optimizing strategic layout and business structure.
Fengle group joined new fields of urban renewal, rural revitalization, medical technology, modern agriculture and animal husbandry etc. while expanding its traditional businesses.
Fengle Group headquartered in Zengcheng district, Guangzhou, then set up five management headquarters in South China, North China, East China, Southwest and Northwest China, achieving nationalization of region and products.
Fengle Group operates in more than 10 countries and regions and creates an annual output value of more than 10 billion yuan.
Guangzhou Fengle Medical Technology Co., Ltd. was founded by the parent company Guangdong Fengle Group Co.,Ltd. The face mask plant of Fengle Medical covers an area of 15,000 square meters, equipped with automatic mask production equipment, automatic packaging equipment, inspection and testing equipment.
Fengle Medical has been established with fine industry, adhering to the philosophy of value discovery, innovation and enlightenment, dedication and altruism, people-oriented, harmony and honesty, cooperation and sharing, innovation and win-win. It provides customers with a full range of quality and value-added services to achieve customer satisfaction, company satisfaction, social satisfaction. Due to rigorous, scientific, efficient and reasonable management system, the company's operation is more standardized, that become a leader in the local industry, developing steadily, rapidly and efficiently.
At present, the company's main products are: Disposable protective masks, disposable children's masks, disposable medical masks, medical surgical masks, KN95 protective masks etc. All the products have obtained the full performance Inspection and Test Report, in line with the relevant national standards and requirements. The company has obtained the ISO 13485 quality system certification, obtained the European Union CE certification, the United States FDA listing for the record, and listed in the "China Chamber of Commerce for Import and Export of Medicines and Health Products Double White List".
Health care is a sunrise industry forever. Fengle Group will take Fengle Medical Technology Co., Ltd as the starting point to build a comprehensive and integrated medical health industry base in the region by connecting with Zhongguancun and the provincial venture capital medical devices, classification diagnosis and treatment, remote diagnosis, health, research and development, and venture capital big data resources.

investment fund

成立于2017年11月20日
是一个以科技创新引领现代生物医药的企业。天津凌视科技有限公司致力于利用光电子成像和人工智能等技术为细胞分析提供智能服务，为生命科学细胞检测和生物制药相关的各类企业，提供技术支撑与产品服务。凌视科技的主要产品是：超高速激光扫描显微成像分析仪。 超高速流式成像分析仪是数字显微技术、微流体力学和图像处理技术的综合应用，用于自动分析颗粒或液体中的悬浮细胞。

A pioneer investment bank focusing on all tracks of potential targets

早期创业投资，关注医疗健康方向。